Author/Authors :
Mustafa, Lirim SHPK, Kosova , Ilazi, Ali Kosovo Occupational Health Institute - Clinical Centre, Kosova , Dauti, Arta University of Prishtina.Clinical Centre N.N. - Faculty of Medicine - Department of Pharmacy, Kosova , Islami, Pellumb Kosovo Medicines Agency, Kosova , Kastrati, Bashkim University of Prishtina.Clinical Centre N.N. - Faculty of Medicine - Department of Pharmacy, Kosova , Islami, Hilmi University of Prishtina - Faculty of Medicine, Clinical Centre - Department of Pharmacology, Kosova
Abstract :
Objective: In this work, effect of tamsulosin as antagonist of alpha1A and alpha1B adrenergic receptor and effect of agonists of beta2 adrenergic receptor–salbutamol in patients with increased bronchial reactibility was studied. Methods: Parameters of the lung function are determined with Body plethysmography six (6) hours after administration of tamsulosin. Raw and ITGV were registered and specific resistance (SRaw) was calculated as well. Tamsulosin was administered in per os manner as a preparation in the shape of the capsules with a brand name of “Prolosin”, produced by Niche Generics Limited, Hitchin, Herts. Results: After six (6) hours of administration of tamsulosin,results gained indicate that blockage of alpha1A and alpha1B-adrenergic receptor (0.8 mg per os) has not changed significantly (p 0.1) the bronchomotor tonus of tracheobronchial tree in comparison to the check-up that has inhaled salbutamol agonist of adrenergic beta2 receptor (2 inh. x 0.2 mg), (p 0.05). Blood pressure suffered no significant decrease following administration of the 0.8 mg dose of tamsulosin. Conclusion: This suggests that even after six hours of administration of tamsulosin, and determining of lung function parameters, the activity of alpha1A and alpha1B-adrenergic receptor in the smooth bronchial musculature has not changed in patients with increased bronchial reactibility.
